* HIDDEN GEMS: Auraria Library
   
* Five questions for Claudia Mills
   
* CU-Boulder professor named top scientist at NASA
   
* Town-and-gown partnerships to be topic of Boulder conference
   
* Proposals sought for Spring Conference on Teaching
   
* People
   
* Did you know...
   
* Letters to the editor
 
 NEWS FROM THE CU SYSTEM
 
  CU-BOULDER
  Health education a crucial aspect of freshman orientation
 
  UCCS
  Emergency weather alerts available by text message
 
  UC DENVER
  Giving Back: For HR team, it's all about the people
 
  ANSCHUTZ MEDICAL CAMPUS
  CU-developed lung cancer therapy proves successful
 
Download Newsleter in PDF
 

Home
Newsletter Archive
Letters to the Editor
Contact Us

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

News from the CU system - Anschutz Medical Campus

CU-developed lung cancer therapy proves successful

Paul Bunn, M.D. Fred Hirsch, M.D., Ph.D.
A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from a double-blind, placebo-controlled phase 2 trial run by Syndax Pharmaceuticals.

The phase 2 results show that the combination of entinostat (Syndax's SNDX-275) and erlotinib was more effective in treating NSCLC in patients with elevated levels of the molecular cancer marker E-cadherin than using erlotinib alone. University of Colorado Cancer Center researchers, who are faculty at the University of Colorado School of Medicine, were the first to identify elevated E-cadherin as a targetable cancer marker, the first to develop the biomarker tumor testing process for elevated E-cadherin, and the first to test the combined therapy.

About 40 percent of NSCLC patients have elevated E-cadherin levels, making this a significant advance toward highly personalized treatment for lung cancer patients. Entinostat controls expression of genes that can cause resistance to conventional cancer therapies like erlotinib.

"The outcome of patients with advanced lung cancer has been disappointing historically but the identification of new molecular features and new therapies directed at these molecular features has markedly improved outcome for some patients," said Paul Bunn, M.D., professor of medical oncology at the CU medical school and principal investigator of the University of Colorado Cancer Center's Specialized Program of Research Excellence in Lung Cancer, funded by the National Cancer Institute.

"Unfortunately, some of the molecular changes are quite rare," Bunn said. "A more common molecular change is the high expression of epithelial markers such as Ecadherin. HDAC inhibitors such as etinostat can increase the expression of epithelial markers and can delay the development of resistance to EGFR inhibitors such as erlotinib. In this study, the combination of erlotinib and the HDAC inhibitor etinostat led to a small but not statistically significant improvement in survival in unselected patients but a large and statistically significant improvement in survival in patients with high expression of Ecadherin ( 9.4 months vs.5.4 months). While extremely promising, these results will need to be confirmed in a larger randomized phase III trial."

Said University of Colorado Cancer Center researcher Fred Hirsch, M.D., Ph.D., professor of medical oncology at the CU medical school, "Using a biomarker to select patients based on the tumor biology can improve patient outcomes versus treating an unselected patient population."

Data from the phase 2 trial, led by Robert Jotte, M.D., Ph.D., of Denver's Rocky Mountain Cancer Center, was presented recently at the ASTRO 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, co-sponsored by the American Society for Radiation Oncology, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer and The University of Chicago.

"The data presented suggest that NSCLC patients with elevated E-cadherin levels can do better when treated with entinostat and erlotinib," said Joanna Horobin, M.D., president and chief executive officer of Syndax, the company that holds worldwide rights to entinostat.

Syndax holds rights to the CU intellectual property related to this type of combination therapy that includes the use of E-cadherin to predict responsiveness to the therapy.

"Syndax has been a model commercial partner for the University, and we are both encouraged and excited by the Phase 2 results," said David Poticha, senior licensing manager at the CU Technology Transfer Office.

For more information regarding the presentation please visit http://www.thoracicsymposium.org/.

Bookmark - Print - Share

 
Previous Anschutz Medical Campus Stories

12/08/2010
School of Medicine to team with Duke in researching quality-of-life care

12/01/2010
Doctors investigate not-so-sweet side of fructose

11/17/2010
Operator of new child care center to host Q&A sessions for parents

11/15/2010
Study pinpoints first lung cancer screening test

11/03/2010
Patients with specific lung cancer respond to new targeted treatment

10/27/2010
Study: Estrogen replacement therapy speeds ovarian cancer growth

10/20/2010
Hospital ranked among top 10 academic medical centers in U.S.

10/13/2010
School of Medicine doctors to provide AIDS care education in Africa

10/06/2010
Low-cost cervical cancer vaccine moves to human trials

09/29/2010
Could brain abnormalities cause antisocial behavior and drug abuse in boys?

09/22/2010
Colorado School of Public Health wins $3.2 million grant

09/15/2010
CU Depression Center data indicates large rise in Colorado suicides last year

09/08/2010
Youth with disabilities gear up and get their game on

09/01/2010
CU Depression Center data indicates large rise in Colorado suicides last year

08/18/2010
First Dinner in White could launch annual series of cancer fundraisers

08/11/2010
College of Nursing awarded grant for leadership in rural, underserved areas

07/28/2010
University of Colorado Hospital ranks high on U.S. News lists

07/14/2010
People with rare cancers needed to help scientists leading new program

06/30/2010
First-in-nation program focuses on anti-cancer stem cell therapies

06/16/2010
UCH receives prestigious nursing designation

06/02/2010
University of Colorado Hospital moves forward with $400 million expansion

05/26/2010
Cancer patients win big as governor signs patient access bills into law

05/12/2010
Study: Many pregnant women not getting enough vitamin D

05/05/2010
Breakthrough treatment extends lives of prostate cancer patients

04/28/2010
Some pediatric brain tumors might be worsened by immune gene expression

04/21/2010
School of Medicine, partners will work to prevent mistreatment of children

04/14/2010
University of Colorado Hospital provides funding for new crisis services system

04/07/2010
University of Colorado Cancer Center researchers receive $3.5 million grant

03/31/2010
Hospital receives distinguished designation for excellence in nursing

03/24/2010
Regional stem-cell center launched by School of Medicine

03/17/2010
School of Medicine program receives oral health grant

03/10/2010
UC Denver one of top places for postdocs to work

03/03/2010
University of Colorado Hospital internal medicine, specialty clinic relocating

02/24/2010
New type of complex genetic variation discovered

02/17/2010
UC Denver announces state's first bioengineering department

02/10/2010
School of Dental Medicine gives kids a smile

02/03/2010
Emergency medicine physicians take part in suicide research trial

01/27/2010
Researchers receive grant to study impact of law on public health practice

01/20/2010
Assembling planet's Tree of Life less daunting thanks to researchers

01/13/2010
State-of-the-art imaging offers enhanced treatment for arrhythmia

01/06/2010
Rural medicine, Down syndrome programs receive federal support

12/16/2009
Study highlights lack of knowledge regarding hospital medications

12/09/2009
School of Pharmacy researcher receives funding from Michael J. Fox Foundation

12/02/2009
New UC Denver program puts high school grads on pathway to med school

11/18/2009
Award of $577,000 will aid study of tuberculosis treatment

11/11/2009
Depression Center works to establish national network

11/04/2009
School of Medicine to take part in nationwide study of blood pressure

10/28/2009
College of Nursing expands offerings in Western Regional Graduate Program

10/21/2009
Study: Tanning associated with moles in very light-skinned children

10/14/2009
When the laboratory meets the studio

10/07/2009
When the laboratory meets the studio

09/30/2009
Cancer Center scientists win $870,000 ARRA Challenge Grant

09/23/2009
Cancer Center scientists win $870,000 ARRA Challenge Grant

09/16/2009
University of Colorado Cancer Center wins National Cancer Institute grant

09/02/2009
Ground broken on planned VA medical center

08/19/2009
SOM, state labor department to manage training facility

08/06/2009
Pulmonary hypertension drug helps former smokers

07/23/2009
Breast cancer researcher receives gift from Avon